Ex-British Prime Minister Calls for Rare Disease Licensing Reform - European Medical Journal

This site is intended for healthcare professionals

Ex-British Prime Minister Calls for Rare Disease Licensing Reform

Author :

Key Summary:

  • Lord Cameron urges regulatory reform and government backing to accelerate rare disease treatment.
  • Genomic data could support earlier diagnosis, research and clinical trial recruitment.
  • Charity founder, Vitarello, called for scalable development and funded access to individualised medicines.
genome sequencing for rare diseases

FORMER UK Prime Minister Lord David Cameron has called for changes to how rare disease treatments are licensed, alongside stronger government backing, drawing on his own experience of losing his son, Ivan.

Speaking at the DIA-MHRA Global Summit in London, Cameron joined Julia Vitarello, Founder of Mila’s Miracle Foundation Inc., during the session, Advanced Therapies for Rare Diseases: From Breakthrough Science to Sustainable Patient Access. Both argued that healthcare and regulatory systems must evolve to translate scientific advances into accessible treatments.

Personal Loss Drives Calls for Change

Cameron recalled losing his son Ivan, who had severe childhood epilepsy and experienced frequent seizures as well as severe developmental delays. After a prolonged search for answers, Ivan, who was diagnosed with Ohtahara syndrome, died in 2009, aged six.

Cameron, who was UK Prime Minister and Conservative Party leader between May 2010 to July 2016, ow chairs the Advisory Council to Oxford-Harrington Rare Disease Centre’s, which aims to advance and deliver 40 new life-changing therapies for rare diseases into clinical trials by 2034.

Reflecting on the importance of understanding a condition’s cause after seeking answers for so long, Cameron said: “Even that gives you some peace of mind, because the diagnostic odyssey is terrible.”

Vitarello described her own daughter Mila’s diagnosis with Batten disease, a 100% fatal genetic condition. Working with Boston Children’s Hospital, she helped advance an individualised antisense oligonucleotide targeting Mila’s disease-causing mutation.

By mapping Mila’s entire genome, scientists uncovered a unique mutation that was causing her disease. They designed the drug, tested it on Mila’s cells and on animals in the laboratory and won approval to use it from the US Food and Drug Administration. Mila was treated with the drug – named Milasen – on 31 January 2018.

Drugs normal take around a decade-and-a-half to get from the laboratory, go through clinical trials and get to patients but the US team got there in a year – something which Mila’s mum argued should be the norm for all rare disease therapies.

Mila died in 2021. The foundation which her mother built on her legacy now supports research and efforts to make individualised medicines routinely accessible across rare diseases.

Genomics Must Inform Research and Care

Cameron discussed the 100,000 Genomes Project launched during his premiership, a British initiative to sequence and study the role our genes play in health and disease by mapping the whole-genomes of NHS patients.

Cameron highlighted the value of linking genomic information such as this with clinical data to understand disease and identify potential treatments.

He advocated using newborn genome sequencing to build knowledge beyond conditions already treatable, arguing that identifying patients with currently untreatable disorders could support future research and trial recruitment.

Cameron encouraged researchers and patient organisations to investigate shared mechanisms across related conditions, including rare childhood epilepsies and rare cancers.

“Let’s try and work out what they have in common,” he said, suggesting that studying conditions together instead of one of the hundreds and thousands that exist at a time, could help accelerate progress towards treatments.

Vitarello similarly argued that developing one medicine for one disease at a time could not address the scale of unmet need. She called for scientifically justified approaches that allow shared development processes across multiple individualised treatments.

“It’s uncomfortable to change the way that we do things, but we’re talking about access to today’s incredible science,” she said.

Vitarello highlighted the gap between identifying the genetic cause of a disease and enabling patients to access treatment. Whole-genome sequencing, she explained, had uncovered a mutation underlying Mila’s condition, opening the door to the development of a medicine specifically targeting it.

“Science isn’t the limiting factor anymore, right? We have the science to do this,” she said.

Drawing on this experience, Vitarello argued that advances in genomic diagnosis must be matched by regulatory and funding pathways that allow patients to benefit from targeted treatments.

Her point was that existing scientific capabilities could already help more patients, yet access remained constrained by how medicines are developed, authorised, funded and delivered.

For healthcare systems, the challenge was to turn a genetic diagnosis into a treatment opportunity, rather than leave families with an explanation for their child’s condition but no route to care.

Lord Cameron speaks at the DIA-MHRA Global Summit in London.

Cameron Endorses MHRA Framework

Cameron welcomed the Medicines and Healthcare products Regulatory Agency’s proposed Rare Disease Therapies Regulatory Framework, calling it “a great piece of work”, while stressing that implementation would require coordinated government backing.

“I think the task there is to turn that into action,” he said. “I think we will need to get the government on board with the programme and recognise that they will have to help.”

He urged ministers to support the necessary changes, including legislation where required, to ensure regulatory proposals translate into treatment opportunities.

Published for consultation in May 2026, the draft proposes an Investigational Marketing Authorisation allowing controlled early access while clinical and real-world evidence continues to accumulate. It addresses circumstances in which very small patient populations make conventional development pathways impractical.

The document also outlines a proposed approach to licensing individualised medicines through shared design and manufacturing processes, potentially avoiding separate marketing authorisations for every patient-specific variant, subject to evidence supporting quality, safety and efficacy.

Funded Access Must Accompany Innovation

Vitarello stressed that regulatory change must be accompanied by manufacturing capacity, hospital delivery and reimbursement.

Recalling attempts to extend Mila’s treatment approach to other children without exceptional fundraising or prolonged demands on clinicians, she said: “There’s nothing sustainable or scalable about that.”

Both speakers called for coordinated action across researchers, clinicians, regulators, industry and government to deliver treatments at scale.

The MHRA draft acknowledges the funding challenge: regulatory authorisation alone would not guarantee NHS commissioning or reimbursement.

 

Featured image: BillionPhotos.com on AdobeStock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this content.